TCGA-CV-A6K0-01B-21R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.450
- ALLOGRAFT_REJECTION+0.420
- IL6_JAK_STAT3_SIGNALING+0.380
- COAGULATION+0.270
- INTERFERON_GAMMA_RESPONSE+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- UV_RESPONSE_DN+0.250
- HEDGEHOG_SIGNALING+0.220
- INTERFERON_ALPHA_RESPONSE+0.220
- APICAL_SURFACE+0.200
Top 10 suppressed
- MYC_TARGETS_V1-0.550
- MYC_TARGETS_V2-0.510
- MTORC1_SIGNALING-0.490
- OXIDATIVE_PHOSPHORYLATION-0.490
- CHOLESTEROL_HOMEOSTASIS-0.470
- E2F_TARGETS-0.470
- G2M_CHECKPOINT-0.440
- GLYCOLYSIS-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.380
- UV_RESPONSE_UP-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-98-A53H-01A-12R-A262-07 | — | cohortA1 | 0.907 |
| 2 | SRR12202445 | — | — | 0.903 |
| 3 | R132 | — | — | 0.890 |
| 4 | SRR1797234 | — | cohortMD2 | 0.890 |
| 5 | TCGA-97-A4M7-01A-11R-A24X-07 | — | cohortA1 | 0.887 |
| 6 | SRR8518276 | — | A | 0.887 |
| 7 | TCGA-86-A4P7-01A-11R-A24X-07 | — | cohortA1 | 0.885 |
| 8 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.884 |
| 9 | ERR2278882 | — | — | 0.882 |
| 10 | TCGA-55-7816-01A-11R-2170-07 | — | cohortMD2 | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.450 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.110 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.110 | Idelalisib | — uncovered |
| COMPLEMENT | 0.020 | Inavolisib | — uncovered |